A broad swath of the US drug industry takes the Food and Drug Administration to task for proposing that sponsors of “additional conditions for nonprescription use” applications first demonstrate conventional labeling wouldn’t support an OTC switch before submitting an ACNU proposal.
The Pharmaceutical Research and Manufacturers of America captures the overall sense of its comments by saying “the proposed rule might...







